Company profile
Kahimmune Therapeutics
Reexploring the Cancer Immunopeptidome
- Industry
- Biotechnology Research
- Employees
- 4
- Headquarters
- Avignon
- Founded
- 2025
- Office locations
- 1
Kahimmune Therapeutics company summary
Kahimmune Therapeutics is a company in the Biotechnology Research industry, headquartered in Avignon, founded in 2025. On LinkedIn the company has around 4 employees. Its listed specialties include immuno-oncology, neoantigens, dark genome.
What technology does Kahimmune Therapeutics use?
No technologies detected yet. Warmrank rechecks company websites on a rolling basis.
About Kahimmune Therapeutics
Kahimmune Therapeutics is a cutting-edge biotech company focused on reexploring the cancer immunopeptidome to develop next-generation immuno-oncology therapies. Leveraging groundbreaking insights into the “dark genome”, Kahimmune identifies novel neoantigens to create innovative cancer vaccines designed for synergistic combination therapies. Spun off from Gustave Roussy and SATT Paris-Saclay, Kahimmune leverages Kahinomics™, its proprietary neoantigen discovery platform, along with an exclusive IP portfolio. This integrated approach supports the creation of a robust pipeline targeting high‑burden cancers, including pancreatic and colorectal tumors. Backed by an experienced founding team and strategic partnerships, Kahimmune is committed to advancing bold immunotherapy innovations that can transform cancer care.
Specialties
Where is Kahimmune Therapeutics located?
Kahimmune Therapeutics lists 1 location.
Compare companies similar to Kahimmune Therapeutics
More companies in Biotechnology Research.
| Company | Industry | Employees | Founded | Headquarters |
|---|---|---|---|---|
Kahimmune Therapeutics kahimmune.com | Biotechnology Research | 4 | 2025 | Avignon |
 Thermo Fisher Scientific thermofisher.com | Biotechnology Research | 100,779 | - | Waltham, MA |
 Amgen amgen.com | Biotechnology Research | 41,028 | 1980 | Thousand Oaks, CA |
 Biogen biogen.com | Biotechnology Research | 7,742 | - | Cambridge, MA |
 Biocon biocon.com | Biotechnology Research | 11,902 | - | Bangalore, Karnataka |
| Biotechnology Research | 28,679 | - | Bethesda, MD | |
 Genentech gene.com | Biotechnology Research | 18,296 | 1976 | South San Francisco, California |
 Eurofins eurofins.com | Biotechnology Research | 24,928 | - | Luxembourg, Luxembourg |
 Gilead Sciences gilead.com | Biotechnology Research | 14,743 | - | Foster City, CA |
 Syneos Health syneoshealth.com | Biotechnology Research | 23,772 | - | Morrisville, NC |
 Moderna modernatx.com | Biotechnology Research | 6,238 | 2010 | Cambridge, Massachusetts |
Frequently asked questions about Kahimmune Therapeutics
What does Kahimmune Therapeutics do?
Kahimmune Therapeutics is a cutting-edge biotech company focused on reexploring the cancer immunopeptidome to develop next-generation immuno-oncology therapies. Leveraging groundbreaking insights into the “dark genome”, Kahimmune identifies novel neoantigens to create innovative cancer vaccines designed for synergistic combination therapies. Spun off from Gustave Roussy and SATT Paris-Saclay, Kahimmune leverages Kahinomics™, its proprietary neoantigen discovery platform, along with an exclusive IP portfolio. This integrated approach supports the creation of a robust pipeline targeting high‑burden cancers, including pancreatic and colorectal tumors. Backed by an experienced founding team and strategic partnerships, Kahimmune is committed to advancing bold immunotherapy innovations that can transform cancer care.
How many employees does Kahimmune Therapeutics have?
Kahimmune Therapeutics has around 4 employees on LinkedIn.
Where is Kahimmune Therapeutics headquartered?
Kahimmune Therapeutics is headquartered in Avignon.
When was Kahimmune Therapeutics founded?
Kahimmune Therapeutics was founded in 2025.
Build a lead list from companies like Kahimmune Therapeutics
Describe your ICP or import a CSV. Warmrank finds matching companies, enriches contacts with verified emails, and tracks every lead.